Compare Stocks

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.53 +1.2%	$0.00	$1.07 ▼ $5.26	$90.37M	0.85	14,169 shs	4,671 shs
MTFB MOTIF BIO PLC/S	$0.11	$0.10	$0.08 ▼ $11.50	N/A	N/A	N/A	867,698 shs
PAS Pascal Biosciences	C$0.02 -25.0%	C$0.02	C$0.02 ▼ C$0.10	C$984K	1.51	52,289 shs	4,000 shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MTFB MOTIF BIO PLC/S	0.00%	0.00%	0.00%	0.00%	0.00%
PAS Pascal Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.4782 of 5 stars	3.5	5.0	0.0	0.0	0.6	1.7	0.6
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$7.00	176.59% Upside
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TRIL, HEMO, PAS, ARMP, and MTFB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/22/2024	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$4.53M	20.20	N/A	N/A	($0.89) per share	-2.84
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	C$0.00 per share	55.00	C($0.02) per share	N/A
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$69.04M	-$1.98	N/A	N/A	N/A	-1,524.51%	-280.95%	-52.61%	5/9/2024 (Estimated)
MTFB MOTIF BIO PLC/S	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	-C$0.01	N/A	∞	N/A	N/A	N/A	-340.40%	N/A
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest TRIL, HEMO, PAS, ARMP, and MTFB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	ARMP Armata Pharmaceuticals	N/A	-$0.55	-$0.55	-$0.55	$0.68 million	$1.53 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A
PAS Pascal Biosciences	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	1.16	1.16
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A
PAS Pascal Biosciences	882.79	0.03	0.17
TRIL Trillium Therapeutics	N/A	19.82	19.82

Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
MTFB MOTIF BIO PLC/S	N/A
PAS Pascal Biosciences	N/A
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	85.50%
MTFB MOTIF BIO PLC/S	N/A
PAS Pascal Biosciences	15.43%
TRIL Trillium Therapeutics	9.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	66	36.15 million	5.24 million	Not Optionable
MTFB MOTIF BIO PLC/S	7	N/A	N/A	Not Optionable
PAS Pascal Biosciences	6	65.59 million	N/A	Not Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

TRIL, HEMO, PAS, ARMP, and MTFB Headlines

Source	Headline
	Cachet Bicycle shakes off COVID baytoday.ca - February 25 at 12:23 PM
	Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics chch.com - January 30 at 5:32 PM
	TTI apprehends motorists for illegal removal of clamps, hunt for four others underway bulawayo24.com - January 30 at 5:32 PM
	BridgeBio raises $1.25bn, and other biotech financings pharmaphorum.com - January 19 at 7:18 AM
	Ratio Therapeutics Raises $50M in Series B Financing precisionmedicineonline.com - January 17 at 1:39 PM
	Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com businesswire.com - November 10 at 1:22 PM
	Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions benzinga.com - November 8 at 1:30 AM
	The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period uk.finance.yahoo.com - July 31 at 9:03 AM
	Ratio Therapeutics unveils new research and development facility biopharma-reporter.com - May 15 at 10:33 AM
	WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death' msn.com - April 26 at 12:18 AM
	Leukemia Therapeutics Global Market Report 2023 uk.finance.yahoo.com - April 4 at 10:35 AM
	Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck finance.yahoo.com - March 28 at 9:12 AM
	Trillium House, an affordable housing project in Warrenton, close to completion dailyastorian.com - January 10 at 12:26 AM
	FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma nz.finance.yahoo.com - October 19 at 9:39 AM
	Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment seekingalpha.com - September 14 at 9:48 AM
	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors nz.finance.yahoo.com - September 12 at 7:55 AM
	Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed seekingalpha.com - August 17 at 11:07 AM
	TTI reviews parking model chronicle.co.zw - August 10 at 10:41 PM
	TTI working round the clock to configure its systems chronicle.co.zw - August 10 at 10:41 PM
	Pfizer in advanced talks to buy firm making sickle cell drugs pmnewsnigeria.com - August 7 at 3:57 AM
	10 Psychedelics CEOs To Pay Attention To In 2022 markets.businessinsider.com - June 22 at 10:08 AM
	Highlights from ASCO Annual Meeting 2022 healio.com - June 15 at 1:37 PM
	Chlormethine gel may be more effective than ointment for mycosis fungoides healio.com - May 27 at 4:34 PM
	Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling? edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Wendy’s Stock Could Be Your Best Passive Income Stock
April 9, 2024 7:45 AM
View Wendy’s Stock Could Be Your Best Passive Income Stock
Breakout Alert: Coinbase's Consolidation Is About To End
April 12, 2024 9:45 AM
View Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
April 12, 2024 10:00 AM
View You Can Follow BlackRock’s Market View for Your Money
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
April 15, 2024 7:40 AM
View Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
Is Zoom Video Stock Getting Too Cheap to Pass Up?
April 24, 2024 7:06 AM
View Is Zoom Video Stock Getting Too Cheap to Pass Up?

All Headlines

Company Descriptions

Armata Pharmaceuticals

NYSEAMERICAN:ARMP

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

MOTIF BIO PLC/S

NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Pascal Biosciences

CVE:PAS

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Trillium Therapeutics

NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial